Table 1.
Baseline characteristics of the study population.
| Overall N = 135 |
Non-CAD N = 20 |
CAD | p-value | |||
|---|---|---|---|---|---|---|
| 1-vessel disease N = 62 |
2-vessel disease N = 29 |
3-vessel/LM disease N = 24 |
||||
| Demographics | ||||||
| Age, years | 62.0 (56.0–69.0) | 58.5 (53.5–66.8) | 61.5 (55.8–68.0) | 62.0 (55.5–70.0) | 65.0 (60.0–69.5) | 0.170 |
| Male, % | 71 (52.6) | 10 (50.0) | 31 (50.0) | 16 (55.2) | 14 (58.3) | 0.902 |
| Body mass index, kg/m2 | 25.0 (23.0–27.0) | 26.0 (24.3–26.9) | 25.0 (23.0–27.0) | 26.0 (24.0–27.5) | 24.0 (22.0–27.0) | 0.282 |
| Risk factors | ||||||
| Current smoking, % | 61 (45.2) | 8 (40.0) | 26 (41.9) | 15 (51.7) | 12 (50.0) | 0.753 |
| Hypertension, % | 97 (71.9) | 13 (65.0) | 46 (74.2) | 21 (72.4) | 17 (70.8) | 0.895 |
| Diabetes, % | 45 (33.3) | 3 (15.0) | 25 (40.3) | 7 (24.1) | 10 (41.7) | 0.102 |
| Hyperlipidemia, % | 73 (54.1) | 8 (40.0) | 38 (61.3) | 14 (48.3) | 13 (54.2) | 0.360 |
| Family history, % | 38 (28.1) | 9 (45.0) | 13 (21.0) | 8 (27.6) | 8 (33.3) | 0.196 |
| Lab examinations | ||||||
| Total triglyceride, mmol/L | 1.6 (1.2–2.5) | 2.0 (1.3–3.2) | 1.7 (1.2–2.4) | 1.5 (1.2–2.4) | 1.4 (0.9–2.6) | 0.316 |
| Total cholesterol, mmol/L | 5.1 (4.1–5.9) | 5.2 (4.7–5.8) | 5.1 (4.1–5.9) | 5.2 (4.0–5.7) | 4.7 (3.8–6.1) | 0.680 |
| LDL-C, mmol/L | 3.2 (2.6–3.7) | 3.0 (2.6–3.5) | 3.2 (2.6–3.8) | 3.2 (2.5–3.5) | 3.3 (2.4–3.9) | 0.903 |
| Glycosylated hemoglobin, % | 6.0 (5.6–6.8) | 6.2 (5.7–6.9) | 5.9 (5.6–6.7) | 6.0 (5.5–6.6) | 6.2 (5.6–7.7) | 0.540 |
| Creatinine, umol/L | 63.0 (53.0–73.0) | 58.0 (50.3–68.0) | 66.0 (55.0–74.0) | 65.0 (53.0–74.0) | 61.5 (47.8–72.8) | 0.216 |
| hs-CRP, mg/L | 1.6 (0.8–3.5) | 0.9 (0.3–1.7) | 1.6 (0.6–3.1) | 2.0 (1.0–4.2)* | 2.7 (1.2–4.5)* | 0.005 |
| White blood cell, *109/L | 6.2 (5.4–7.4) | 6.1 (5.4–7.1) | 6.2 (5.4–7.3) | 6.4 (5.4–8.6) | 5.7 (5.4–6.5) | 0.610 |
| Hemoglobin, g/L | 132.0 (124.0–143.0) | 132.0 (126.0–143.0) | 134.0 (123.0–144.3) | 130.0 (124.0–144.0) | 133.5 (125.3–145.0) | 0.915 |
| Platelet, *109/L | 202.0 (161.0–245.0) | 212.0 (175.8–229.0) | 192.0 (145.5–233.5) | 222.0 (168.5–256.0) | 214.0 (155.8–251.8) | 0.191 |
| Echocardiography | ||||||
| LVEF, % | 66.0 (61.0–71.0) | 65.5 (61.3–69.5) | 66.0 (61.0–72.0) | 67.0 (61.0–72.5) | 63.5 (60.5–68.0) | 0.754 |
| LVEDD, mm | 46.0 (44.0–49.0) | 46.5 (44.0–49.0) | 46.0 (44.0–49.0) | 44.0 (42.0–46.0) | 46.0 (44.0–48.8) | 0.112 |
| IVSD, mm | 9.0 (8.0–10.0) | 9.0 (8.1–9.8) | 9.0 (8.0–10.0) | 8.0 (7.0–9.5) | 9.0 (8.0–10.0) | 0.285 |
Data shown as median (interquartile range), or number (percent) as appropriate.
A p-value was calculated by the Kruskal-Wallis H test.
CAD, coronary artery disease; hs-CRP, hypersensitive-C-reactive protein; IVSD, interventricular septal thickness at diastole; LM, left main; LDL-C, low density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter.
*
Indicated Bonferroni adjusted p < 0.05 compared to Non-CAD group.